Pancreatic Cancer Research

ResearcherEnte Ospedaliero CantonaleActive in the last 2 years

Sara De Dosso

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6424-6307; OpenAlex author ID A5069819572. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients? Co-author DOI 10.3390/cancers15174398↗
  3. Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes. Last author DOI 10.3390/cancers15184627↗
  4. Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review. Co-author DOI 10.3389/fonc.2022.974116↗
  5. Treatment landscape of metastatic pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2021.102180↗
  6. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pan… Co-author DOI 10.1093/annonc/mdx343↗
  7. Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s12029-015-9705-4↗
  8. Chemotherapy in patients with advanced pancreatic cancer: too close to death? First author DOI 10.1007/s00520-012-1505-9↗
  9. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1159/000330769↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marco Cefalì · 3 shared papers, 2022–2023 · strength 0.49
  2. Stefania Rizzo · 2 shared papers, 2022–2023 · strength 0.32
  3. Filippo Del Grande · 2 shared papers, 2022–2023 · strength 0.32
  4. Ralph Fritsch · 2 shared papers, 2021–2023 · strength 0.30
  5. Dieter Koeberle · 2 shared papers, 2011–2023 · strength 0.19
  6. Maria Celeste Palmarocchi · 1 shared paper, 2023 · strength 0.17
  7. Raffaello Roesel · 1 shared paper, 2023 · strength 0.17
  8. Saskia Hussung · 1 shared paper, 2023 · strength 0.16
  9. Markus Borner · 1 shared paper, 2021 · strength 0.14
  10. Piercarlo Saletti · 3 shared papers, 2011–2015 · strength 0.14
  11. Beate S. Schultheis · 1 shared paper, 2017 · strength 0.05
  12. Markus Dommach · 1 shared paper, 2017 · strength 0.05
  13. Wolfgang Ekkehard Schmidt · 1 shared paper, 2017 · strength 0.05
  14. Ralf‐Dieter Hofheinz · 1 shared paper, 2017 · strength 0.05
  15. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
  16. Dirk Strumberg · 1 shared paper, 2017 · strength 0.05
  17. Şuayib Yalçın · 1 shared paper, 2017 · strength 0.05
  18. Mauro Frigeri · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.